Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
The CEO of Facebook said he’ll send a representative to a meeting the FDA wants on ways to curtail opioid abuse.
Mark Zuckerberg told a joint Senate panel as part of a hearing April 10 that he’ll respond to Food and Drug Administration Commissioner Scott Gottlieb’s request that tech and social media companies do their part to fight the epidemic of pain drug abuse.
“Senator, that sounds like an important initiative, and we will send someone,” Zuckerberg said in response to Republican Sen. Shelley Moore Capito of West Virginia.
Capito had asked the Facebook CEO for a commitment, noting that Gottlieb “called upon social media and internet service providers, and he mentioned Facebook when he talked about it, to try to disrupt the sale—the sale of illegal drugs and particularly the powerful opioid, Fentanyl, which has been advertised and sold online.”
The West Virginia Republican said to Zuckerberg, “the commissioner is announcing his intention to convene a meeting of chief executives and senior leaders and I want to know: Can I get a commitment from you today that Facebook will commit to having a representative with Commissioner Gottlieb to finalize ... this meeting?”
The Senate’s hearing with the social media company’s leader was held by two panels—Judiciary, and Commerce, Science and Transportation—and focused on privacy and other issues. It came the day before the Senate’s health committee and the House Energy and Commerce Committee will hold their own hearings April 11 on legislation to combat opioid abuse.
According to the U.S. Centers for Disease Control and Prevention, on average, 115 Americans die every day from an opioid overdose.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)